The Scottish Medicines Consortium (SMC) has approved Tecvayli – also known as teclistamab – for patients with relapsed and refractory multiple myeloma (RRMM), making Scotland the first UK nation to accept this innovative treatment within its full licensed indication.

Scotland first in UK to approve new myeloma treatment – PharmaTimes